Charles York II Sells 6,065 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles York II sold 6,065 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $70,354.00. Following the sale, the chief financial officer owned 312,025 shares in the company, valued at approximately $3,619,490. The trade was a 1.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Day One Biopharmaceuticals Price Performance

NASDAQ DAWN traded down $0.32 during mid-day trading on Wednesday, reaching $11.56. The stock had a trading volume of 1,478,926 shares, compared to its average volume of 2,543,632. The stock has a market cap of $1.19 billion, a PE ratio of -7.61 and a beta of -1.26. Day One Biopharmaceuticals, Inc. has a 1 year low of $5.64 and a 1 year high of $13.20. The company has a fifty day moving average price of $10.28 and a 200 day moving average price of $8.55.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. TD Cowen started coverage on Day One Biopharmaceuticals in a report on Tuesday, January 13th. They issued a “buy” rating and a $34.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research report on Monday, December 29th. Piper Sandler lifted their target price on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Finally, Zacks Research raised Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $25.71.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of DAWN. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Day One Biopharmaceuticals by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock worth $46,000 after purchasing an additional 1,029 shares in the last quarter. Federated Hermes Inc. bought a new stake in Day One Biopharmaceuticals during the third quarter valued at about $39,000. Quarry LP purchased a new stake in Day One Biopharmaceuticals in the third quarter worth about $49,000. Ameritas Investment Partners Inc. raised its stake in shares of Day One Biopharmaceuticals by 44.5% in the second quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock worth $48,000 after buying an additional 2,264 shares during the period. Finally, CWM LLC lifted its position in shares of Day One Biopharmaceuticals by 32.4% during the 4th quarter. CWM LLC now owns 8,373 shares of the company’s stock valued at $78,000 after buying an additional 2,051 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.